An Open-label, Randomized, Three-period, Three-treatment, Crossover, Single-centre, Single-dose Study to Assess the Bioequivalence Between Ticagrelor Orodispersible Tablets and Ticagrelor Immediate-release Tablets in Healthy Japanese Subjects.
Phase of Trial: Phase I
Latest Information Update: 26 Sep 2017
At a glance
- Drugs Ticagrelor (Primary)
- Indications Abdominal aortic aneurysm; Acute coronary syndromes; Cardiovascular disorders; Community-acquired pneumonia; Coronary artery disease; Sickle cell anaemia; Stroke
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 26 Sep 2017 New trial record
- 30 Aug 2017 Results of pooled data from (NCT02400333 and NCT02436577) evaluated pharmacokinetic profiles of orodispersible ticagrelor tablets in healthy western and japanese subjects, were presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.